Comparing the current results to its competitors, Sutro Biopharma Inc reported Revenue decrease in the 2 quarter 2026 year on year by -84.57 %, faster than the overall decrease of Sutro Biopharma Inc 's competitors by -12.48 %, recorded in the same quarter.
Sutro Biopharma Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and biopharmaceutical industries, with a focus on the immuno-oncology subsector. It faces competition from large biopharmaceutical companies, specialty biotechnology firms, academic research departments, and both public and private research institutions. Competitors include well-funded biopharmaceutical, biotechnological, and therapeutics companies, as well as numerous smaller companies. The company's product candidates, if approved, will compete with existing and developing therapeutic treatments such as tumor-targeting monoclonal antibodies, antibody-drug conjugates (ADCs), immune checkpoint inhibitors, T cell-engager immunotherapies, and CAR-T cell therapies.
April 28, 2025
Sutro Biopharma has emerged as a front-runner in the development of innovative cancer therapies. At the upcoming American Association for Cancer Research (AACR) 2025 conference, the company will unveil preclinical findings for its lead candidate, STRO004, a next-generation antibody-drug conjugate (ADC). This article aims to present a view of the anticipated findings which suggest STRO004 s promising antitumor activity and favorable safety profile. Background on Antibody-Drug Conjugates Antibody-drug conjugates represent a therapeutic class that combines the specificity of monoclonal antibodies with the potency of cytotoxic drugs. By selectively targeting cancer cells, these agents aim to enhance anticancer ...
April 30, 2024
Assessing the Impact of Sutro Biopharma s REFRME-O1 Trial on Patients with Platinum-Resistant Ovarian CancerIn recent news, Sutro Biopharma has announced the initiation of the randomized portion (Part 2) of the REFRME-O1 trial. This trial focuses on evaluating the efficacy of luvelta, a promising drug, in patients suffering from platinum-resistant ovarian cancer (PROC). With this significant development, the medical community eagerly awaits the outcomes. This article aims to outline the facts surrounding the trial initiation and assess its impact on Sutro Biopharma as a company.Facts:1. Sutro Biopharma has initiated the randomized portion (Part 2) of the REFRME-O1 trial.2. The trial aims to assess the effec...
April 2, 2024
Ipsen, a leading global pharmaceutical company, and Sutro Biopharma, a clinical-stage oncology-focused biotechnology company, have recently announced an exclusive global licensing agreement for the development and commercialization of STRO-003. This novel antibody-drug conjugate (ADC) is in advanced stages of pre-clinical development and is designed to target the ROR1 tumor antigen, which is known to be overexpressed in a wide range of cancer types, including both solid tumors and hematological malignancies.Under the terms of the agreement, Ipsen has been granted exclusive worldwide rights to advance the development and commercialization of STRO-003. This collaboration marks a significant milestone for both ...
Luveltamab Tazevibulin, more commonly known as luvelta, exhibited complete remission in 42% of patients with CBF/GLIS Acute Myeloid Leukemia (AML) having 5% blasts, while an impressive 75% remission rate was noted in pediatric patients suffering from the same condition with less than 5% blasts. The remission occurred whether luvelta was used as a standalone therapy or in combination with other treatments. This pivot to the robust and transformative research represents a beacon of hope for those dealing with the relentless battle against CBF/GLIS AML, particularly children. This discovery could potentially lead to more effective treatments in the future, enhancing patient prognosis and survival rates...
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.
Sources:
Sutro Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sutro Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
